Shilpa Medicare clears USFDA review for Dabaspet facility
Advertisement
Hyderabad: Shilpa Medicare Limited has recently announced that United States Food and Drug Administration (USFDA) has concluded Remote Record Review of the company, Unit III, Research and Development facility situated at Dabaspet, Bengaluru, Karnataka without any objectionable conditions or observations.
"The review was conducted during 15th to 18th Nov 2021," the company stated in a BSE filing.
Shilpa Medicare Limited, Unit III, R&D facility is involved in development of formulations (generics, complex generics and innovative products) and providing advanced analytical services.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.